Ardelyx, Inc.

ARDX Healthcare Biotechnology

Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.09 0.18 −5.50%
Market cap
$814.9M
P/E
0.0×
Fwd P/E
−122×
Dividend yield
—
F-score
2/9
Altman Z
1.12
Beneish M
−2.40
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — 6 5 3 3 3 2 2
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
— 10.94 38.60 90.24 76.55 11.35 8.15 10.66 3.57 3.45
Altman Z-Score
— 7.54 (2.48) 1.41 0.30 (8.32) (3.07) 2.76 1.20 1.12
Altman Z″-Score (non-manufacturers)
— 4.83 (2.36) 0.35 (4.83) (17.60) (11.47) (5.05) (2.17) (2.34)
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — 1.37 (2.17) — — 3.66 (0.58) (1.05) (2.40)
P/Operating CF
— 70.68 (5.46) (43.48) (32.95) (2.90) 29.77 (152.21) 121.57 67.07
P/B ratio
— 2.38 0.87 2.59 4.60 1.39 4.33 7.95 6.88 8.42
Price to Tangible BV
— 2.38 0.87 2.59 4.60 1.39 4.33 7.95 6.88 8.42
EV/Sales
— 6.52 (7.00) 53.44 58.63 3.96 6.62 9.80 3.36 3.36
EV/EBITDA
— 0.00 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
— (3.04) 0.26 (3.75) (5.45) (0.26) (4.93) (13.59) (25.00) (32.26)
EV/FCF
— (2.93) 0.26 (3.73) (5.43) (0.26) (5.05) (13.54) (24.45) (31.16)
Quick Ratio
10.46 8.10 9.77 11.17 6.56 2.22 2.01 4.09 3.95 3.80
Current Ratio
10.62 8.38 9.95 11.34 6.85 2.53 2.34 4.88 4.58 4.31
Net Debt/EBITDA
1.81 2.16 1.34 2.23 1.54 0.49 1.28 2.17 3.83 1.63
Debt/Assets
0.00% 0.00% 26.84% 19.25% 25.20% 28.02% 23.06% 16.74% 34.62% 40.44%
Debt/Equity
0.00 0.00 0.42 0.27 0.40 0.51 0.45 0.30 0.87 1.21
Asset Turnover
0.00 0.23 0.02 0.02 0.03 0.06 0.31 0.51 0.91 0.87
Operating CF/Net income
0.82 1.01 0.77 0.81 0.86 0.96 1.04 1.36 1.15 0.69
Capex/Depreciation
(2.78) (0.73) (0.15) (0.12) (0.13) (0.67) 1.52 (0.27) (0.49) (0.49)
Interest Coverage
— — (25.73) (15.94) (17.80) (34.28) (12.57) (7.13) (1.39) (1.44)
ROE
(74.42%) (38.70%) (71.57%) (62.78%) (60.31%) (151.55%) (74.28%) (49.83%) (23.01%) (36.21%)
ROA
(68.10%) (34.68%) (53.51%) (42.85%) (40.89%) (90.00%) (39.54%) (27.10%) (10.67%) (13.14%)
ROIC
0.00% (762.69%) 0.00% 0.00% 0.00% (1,214.94%) (218.47%) (122.29%) (23.59%) (24.37%)
Return on Tangible Assets
(58.00%) (46.00%) (55.58%) (40.70%) (56.07%) (190.13%) (75.32%) (33.58%) (13.97%) (20.82%)
Average Days of Receivables
— 93.82 711.94 51.84 0.00 18.15 54.12 64.61 63.13 64.38
Research and Development Expense of Revenue
0.00% 179.72% 2,661.03% 1,357.26% 859.24% 902.64% 67.49% 28.55% 15.68% 17.56%
Selling, General and Administrative Expense of Revenue
0.00% 55.31% 909.67% 459.52% 437.89% 716.08% 146.86% 107.99% 77.54% 82.79%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 22.83% 353.89% 188.15% 139.78% 119.23% 20.61% 10.87% 11.20% 12.02%
Graham Net Nets
— 0.39 1.08 0.37 0.21 0.58 0.15 0.09 0.08 0.03
Graham Number
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
— (19.43%) (90.50%) (19.71%) (16.23%) (138.18%) (17.91%) (4.96%) (3.22%) (4.36%)
Free Cash Flow Yield
— (20.34%) (70.14%) (15.86%) (14.11%) (134.71%) (16.06%) (6.79%) (3.84%) (3.13%)
Revenue per Share
0.00 0.89 0.05 0.08 0.08 0.10 0.33 0.57 1.42 1.69
Operating CF per Share
(2.31) (1.37) (1.25) (1.19) (0.91) (1.46) (0.44) (0.41) (0.19) (0.18)
Capex per Share
(0.12) (0.05) (0.01) 0.00 0.00 (0.02) 0.01 0.00 0.00 (0.01)
Free Cash Flow per Share
(2.43) (1.42) (1.26) (1.19) (0.91) (1.48) (0.43) (0.41) (0.19) (0.18)
Cash per Share
5.01 2.82 2.99 3.84 2.08 1.12 0.78 0.84 1.06 1.10
Shareholders Equity per Share
4.81 2.94 2.06 2.89 1.41 0.79 0.62 0.76 0.74 0.69
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.81 2.94 2.06 2.89 1.41 0.79 0.62 0.76 0.74 0.69
Free Cash Flow
(97.40) (67.54) (70.58) (76.81) (81.76) (154.42) (68.30) (90.06) (45.82) (43.97)
Working Capital
184.79 131.84 158.64 229.84 166.27 80.83 88.00 195.72 278.62 293.71
Capital Expenditures
(4.87) (2.35) (0.31) (0.32) (0.32) (1.87) 1.74 (0.34) (1.01) (1.49)
Net Current Asset Value
184.01 131.12 108.85 178.94 119.24 66.35 61.87 115.35 93.99 47.66
EV/EBIT
— 0.00 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.06 0.12 0.06 0.04 0.18 (0.03) 0.00 0.00 0.00
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.19 0.40 0.36 0.81 1.31 1.19 0.94 1.28 1.38 1.40
Cash ROIC
(24.72%) (24.72%) (21.19%) (15.86%) (22.50%) (63.99%) (25.67%) (22.46%) (7.98%) (6.93%)
Accounts Receivable Turnover
— 6.28 0.33 1.81 0.00 16.13 12.67 8.36 8.37 6.29
Accounts Payable Turnover
0.31 1.76 0.18 0.36 0.04 0.20 0.54 1.62 3.73 2.24
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.26 3.01 2.03
Average Days of Payables
1,588.24 170.90 899.18 1,330.43 14,162.00 1,561.11 962.72 228.46 115.52 177.57
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 290.97 255.33 152.86 163.73
Average Receivables
— 6.69 7.94 2.92 — 0.63 4.12 14.88 39.87 64.78
Average Payables
4.21 4.78 2.54 1.67 3.91 4.95 7.57 11.00 13.57 17.62
Average Inventory
— — — — — — — 7.87 16.81 19.45
Average Assets
165.04 185.52 170.62 221.56 230.67 175.74 169.99 243.82 366.67 468.68
Average Common Equity
151.03 166.23 127.56 151.23 156.38 104.36 90.47 132.57 170.05 170.12

Fold the line items

Columns are period end dates